During the recent session, Bioline Rx Ltd ADR (NASDAQ:BLRX)’s traded shares were 0.47 million, with the beta value of the company hitting 1.48. The 52-week high for the BLRX share is $1.93, that puts it down -370.73 from that peak though still a striking 4.88% gain since the share price plummeted to a 52-week low of $0.39. The company’s market capitalization is $32.80M, and the average intraday trading volume over the past 10 days was 0.41 million shares, and the average trade volume was 284.40K shares over the past three months.
Bioline Rx Ltd ADR (BLRX) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. BLRX has a Sell rating from 0 analyst(s) out of 1 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 1 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.1.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Bioline Rx Ltd ADR (NASDAQ:BLRX) trade information
Bioline Rx Ltd ADR (BLRX) registered a -0.05% downside in the last session and has traded in the green over the past 5 sessions. The stock plummet -0.05% in intraday trading to $0.41, hitting a weekly high. The stock’s 5-day price performance is 1.23%, and it has moved by -18.81% in 30 days. Based on these gigs, the overall price performance for the year is -73.20%. The short interest in Bioline Rx Ltd ADR (NASDAQ:BLRX) is 0.62 million shares and it means that shorts have 1.94 day(s) to cover.
Bioline Rx Ltd ADR (BLRX) estimates and forecasts
Statistics show that Bioline Rx Ltd ADR has outperformed its competitors in share price, compared to the industry in which it operates. Bioline Rx Ltd ADR (BLRX) shares have gone down -39.71% during the last six months, with a year-to-date growth rate more than the industry average at 73.40% against 18.10. Yet analysts are ramping up their growth forecast for the fiscal year 2024. Revenue is predicted to grow 66.70% this quarter and then jump 33.30% in the quarter after that. In the rating firms’ projections, revenue will increase 322.70% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 4.12M as predicted by 3 analyst(s). Meanwhile, a consensus of 3 analyst(s) estimates revenue growth to 4.74M by the end of current fiscal year.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 21.53%. While earnings are projected to return 85.48% in 2024.
BLRX Dividends
Bioline Rx Ltd ADR is due to release its next quarterly earnings on 2024-Nov-04. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Bioline Rx Ltd ADR (NASDAQ:BLRX)’s Major holders
The next largest institutional holding, with 0.82 million shares, is of CVI HOLDINGS, LLC’s that is approximately 1.126% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $0.46 million.
